論文（英文）

Denda T, Kanda M, Morita Y, Kim HM, Kashiwada T, Matsuda C, Fujieda S, Nakata K, Murotani K, Oba K, Sakamoto J, Mishima H. Pharmacokinetic dose adjustment of 5-FU in modified FOLFOX7 plus bevacizumab for metastatic colorectal cancer in Japanese patients: a-JUST phase II clinical trial. Cancer Chemother Pharmacol 2016;78:1253-1261.
Nomoto H, Miyoshi H, Furumoto T, Oba K, Tsutsui H, Inoue A, Atsumi T, Manda N, Kurihara Y, Aoki S; SAIS Study Group. A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters: Sapporo Athero-Incretin Study 1 (SAIS1). PLoS One. 2016 Oct 6;11:e0164255.
Kataoka M, Kanda M, Ishigure K, Matsuoka H, Sato Y, Takahashi T, Tanaka C, Deguchi T, Shibata Y, Sato M, Inagaki H, Matsui T, Kondo A, Takano N, Tanaka H, Sakamoto J, Oba K, Kondo K. The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer. Ann Surg Oncol. 2016 Sep 8.
Toyoda H, Tada T, Johnson PJ, Izumi N, Kadoya M, Kaneko S, Kokudo N, Ku Y, Kubo S, Kumada T, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kudo M; Liver Cancer Study Group of Japan. Validation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide survey. J Gastroenterol. 2017;52(10):1112-21.
Saitoh A, Saitoh A, Sato I, Shinozaki T, Kamiya H, Nagata S. Effect of stepwise perinatal immunization education: a cluster-randomized controlled trial. Vaccine. 2017;35(12):1645-51.
Jinnouchi H, Kuramitsu S, Shinozaki T, Tomoi Y, Hiromasa T, Kobayashi Y, Domei T, Soga Y, Hyodo M, Shirai S, Ando K. Difference of tissue characteristics between early and late restenosis after second-generation drug-eluting stents implantation: an optical coherence tomography study. Circ J. 2017;81(4):450-7.
Kozuma K, Kashiwabara K, Shinozaki T, Kozuma K, Oba K, Matsuyama Y. Two-by-two cross-over study to evaluate agreement between versions of a quantitative coronary analysis system (QAngio XA). Int J Cardiovasc Imaging. 2017;33(6):779-787. doi: 10.1007/s10554-017-1068-4.
Taniguchi Y, Kitamura A, Murayama H, Amano H, Shinozaki T, Yokota I, Seino S, Nofuji Y, Nishi M, Yokoyama Y, Matsuyama Y, Fujuwara Y, Shinkai S. Mini-Mental State Examination Score Trajectories and Incident Disabling Dementia Among Community-Dwelling Older Japanese. Geriatr Gerontol Int. 2017;17(11):1928-35.
Taniguchi Y, Fujiwara Y, Murayama H, Yokota I, Matsuo E, Seino S , Nofuji Y, Nishi M, Matsuyama Y, Shinkai S. Prospective Study of Trajectories of Physical Performance and Mortality Among Community-Dwelling Older Japanese. J Gerontol A Biol Sci Med Sci. 2016; 71:1492-1499.
Tabuchi T, Goto A, Ito Y, Fukui K, Miyashiro I, Shinozaki T. Smoking at the time of diagnosis and mortality in cancer patients: What benefit does the quitter gain? Int J Cancer. 2017;140(8):1789-95.
Taniguchi Y, Kitamura A, Seino S, Murayama H, Amano H, Nofuji Y, Nishi M, Yokoyama Y, Shinozaki T, Yokota I, Matsuyama Y, Fujiwara Y, Shinkai S. Gait Performance Trajectories and Incident Disabling Dementia Among Community-Dwelling Older Japanese. J Am Med Dir Assoc. 2017;18(2):192.e13-192.e20.
Kudo M, Izumi N, Ichida T, Ku Y, Kokudo N, Sakamoto M, Takayama T, Nakashima O, Matsui O, Matsuyama Y. Report of the 19th follow-up survey of primary liver cancer in Japan. Hepatol Res. 2016; 46(5): 372-90.
Hasegawa K, Saiura A, Takayama T, Miyagawa S, Yamamoto J, Ijichi M, Teruya M, Yoshimi F, Kawasaki S, Koyama H, Oba M, Takahashi M, Mizunuma N, Matsuyama Y, Watanabe T, Makuuchi M, Kokudo N. Adjuvant oral uracil-tegafur with leucovorin for colorectal cancer liver metastases: A randomized controlled trial. PLoS One. 2016; 11(9): e0162400.
Moriya J, Matsuyama Y. Estimating treatment effect of high hemoglobin using the principal stratification approach. Jpn J Biometrics. 2016; 37: 7-22.
Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, Kudo M, Ku Y, Sakamoto M, Nakashima O, Kaneko S, Kokudo N; Liver Cancer Study Group of Japan. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol. 2016; 65(5): 938-943.
Yoshida M, Matsuyama Y. Interim analysis based on the weighted log-rank test for delayed treatment effects under staggered patient entry. J Biopharm Stat. 2016; 26(5): 842-58.
Kitahara H, Waseda K, Sakamoto K, Yamada R, Huang CC, Nakatani D, Sakata K, Kawarada O, Yock PG, Matsuyama Y, Yokoi H, Nakamura M, Muramatsu T, Nanto S, Fitzgerald PJ, Honda Y. Impact of attenuated-signal plaque observed by intravascular ultrasound on vessel response after drug-eluting stent implantation. Atherosclerosis. 2017; 259: 68-74.
Zhu Y, Chen CY, Matsuyama Y, Ohashi Y, Franklin JM, Setoguchi S. Comparative validity of methods to select appropriate cutoff weight for probabilistic linkage without unique personal identifiers. Pharmacoepidemiol Drug Saf. 2016; 25(4): 444-52.
Takahashi M, Hasegawa K, Oba M, Saiura A, Arita J, Sakamoto Y, Shinozaki E, Mizunuma N, Matsuyama Y, Kokudo N. Phase 1 study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases. Invest New Drugs. 2016; 34(4): 468-73.
Kitai S, Kudo M, Nishida N, Izumi N, Sakamoto M, Matsuyama Y, Ichida T, Nakashima O, Matsui O, Ku Y, Kokudo N, Makuuchi M; Liver Cancer Study Group of Japan. Survival benefit of locoregional treatment for hepatocellular carcinoma with advanced liver cirrhosis. Liver Cancer. 2016; 5(3): 175-189.

TOP